• Corpus ID: 16669368

For online use by the Drug Policy Alliance only

@inproceedings{Carlo2002ForOU,
  title={For online use by the Drug Policy Alliance only},
  author={Giulia Di Carlo and Angelo A. Izzo},
  year={2002}
}
∆9-Tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and synthetic cannabinoids, exert many biological functions by activating two types of cannabinoid receptors, CB1 and CB2 receptors. CB1 receptors have been detected on enteric nerves, and pharmacological effects of their activation include gastroprotection, reduction of gastric and intestinal motility and reduction of intestinal secretion. The digestive tract also contains endogenous cannabinoids (i.e., the… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 86 REFERENCES
The neurobiology and evolution of cannabinoid signalling.
  • M. Elphick, M. Egertová
  • Biology
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • 2001
TLDR
A model of cannabinoid signalling is presented in which anandamide is synthesized by postsynaptic cells and acts as a retrograde messenger molecule to modulate neurotransmitter release from presynaptic terminals, concluding that the cannabinoid signalling system may be quite restricted in its phylogenetic distribution.
The endocannabinoid system and the molecular basis of paralytic ileus in mice
  • N. Mascolo, A. Izzo, V. Marzo
  • Biology, Medicine
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2002
TLDR
The intestinal hypomotility typical of paralytic ileus is due, at least in part, to the enhancement of anandamide levels and CB1 expression during this condition, and that selective, nonpsychotropic CB1 receptor antagonists could represent new drugs to treat this disorder.
Molecular characterization of a peripheral receptor for cannabinoids
TLDR
The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids.
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
TLDR
A more thorough characterization of the roles of endocannabinoids in health and disease will be necessary to define the significance ofendocannabinoid inactivation mechanisms as targets for therapeutic drugs.
Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors.
  • P. Reggio
  • Biology, Chemistry
    Prostaglandins, leukotrienes, and essential fatty acids
  • 2002
TLDR
This review considers cannabinoid receptor SAR developed to date for the endocannabinoids with emphasis upon the conformational implications forendocannabinoid recognition at the cannabinoid receptors.
Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development
  • R. Pertwee
  • Biology, Chemistry
    Expert opinion on investigational drugs
  • 2000
This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools or
Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation
TLDR
It is concluded that inflammation of the gut increases the potency of cannabinoid agonists possibly by ‘up‐regulating’ CB1 receptor expression; in addition, endocannabinoids, whose turnover is increased in inflamed gut, might tonically inhibit intestinal motility.
Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.
  • J. Shook, T. Burks
  • Biology, Medicine
    The Journal of pharmacology and experimental therapeutics
  • 1989
TLDR
Intravenous delta 9-tetrahydrocannabinol (delta 9-THC) slowed the rate of gastric emptying and small intestinal transit in mice and in rats, indicating a selectivity for the more proximal sections of the gut.
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.
TLDR
CB1r mediates the anti-emetic action of cannabinoids in the dorsal vagal complex and is found in the myenteric plexus of the stomach and duodenum and a novel neuroregulatory system involved in the control of emesis.
...
1
2
3
4
5
...